Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ploeger

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Molecular Imaging and Biology|December 6, 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomographyLia C Liefaard, Bart A Ploeger, Carla F M Molthoff, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 14, 2012
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humansJasper Stevens, Bart A Ploeger, Margareta Hammarlund-Udenaes, et al.
Clinical Pharmacokinetics|May 23, 2013
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patientsPetra C van Rijn-Bikker, Oliver Ackaert, Nelleke Snelder, et al.
European Journal of Clinical Pharmacology|April 1, 2010
Explaining variability in ciclosporin exposure in adult kidney transplant recipientsRogier R Press, Bart A Ploeger, Jan den Hartigh, et al.
Therapeutic Drug Monitoring|March 5, 2009
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipientsRogier R Press, Bart A Ploeger, Jan den Hartigh, et al.
British Journal of Pharmacology|July 16, 2013
PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious ratsN Snelder, B A Ploeger, O Luttringer, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2016
Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling ApproachNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
American Journal of Hypertension|August 14, 2013
Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial populationPetra C van Rijn-Bikker, Nelleke Snelder, Oliver Ackaert, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
Epilepsia|August 30, 2008
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomographyLia C Liefaard, Bart A Ploeger, Carla F M Molthoff, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Molecular Imaging and Biology|December 6, 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomographyLia C Liefaard, Bart A Ploeger, Carla F M Molthoff, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 14, 2012
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humansJasper Stevens, Bart A Ploeger, Margareta Hammarlund-Udenaes, et al.
Clinical Pharmacokinetics|May 23, 2013
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patientsPetra C van Rijn-Bikker, Oliver Ackaert, Nelleke Snelder, et al.
European Journal of Clinical Pharmacology|April 1, 2010
Explaining variability in ciclosporin exposure in adult kidney transplant recipientsRogier R Press, Bart A Ploeger, Jan den Hartigh, et al.
Therapeutic Drug Monitoring|March 5, 2009
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipientsRogier R Press, Bart A Ploeger, Jan den Hartigh, et al.
British Journal of Pharmacology|July 16, 2013
PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious ratsN Snelder, B A Ploeger, O Luttringer, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2016
Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling ApproachNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
American Journal of Hypertension|August 14, 2013
Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial populationPetra C van Rijn-Bikker, Nelleke Snelder, Oliver Ackaert, et al.
Clinical and Translational Science|March 29, 2019
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid CancerJoachim Grevel, Garrit Jentsch, Rupert Austin, et al.
Epilepsia|August 30, 2008
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomographyLia C Liefaard, Bart A Ploeger, Carla F M Molthoff, et al.
Pageof 7